UNSPSC 51111731: Bevacizumab

This classification denotes a monoclonal antibody anti-vegf with the molecular formula C6638H10160N1720O2108S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S9ZZM9Q9V, more generally known as bevacizumab. European Medicines Agency schedules bevacizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16402MIG. The term BEVACIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.

Most nations schedule Bevacizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, BEVACIZUMAB remains the US FDA Preferred Term for this commodity.. Bevacizumab bears US NLM identifiers UMLS ID C0796392 and NCI Concept Code C2039.

UNSPSC 51111731 Bevacizumab, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities posted under this code do not involve bevacizumab or other oncology pharmaceuticals at all. The Illinois Department of Public Health awarded a completed piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for Doxycycline Hyclate and Ciprofloxacin Hydrochloride—both antibiotics used for infectious disease, not cancer treatment. Seminole County, Florida posted an IFB on June 30, 2026, seeking Naloxone and Safe Drug Deactivation Systems for community health initiatives, which are harm-reduction and substance-abuse products, also outside bevacizumab's therapeutic class. Neither opportunity reflects state or local procurement of bevacizumab or similar biologic cancer therapeutics.

The mismatch between the code's stated scope and the recent opportunities suggests either miscoding by the issuing bodies or that the code sees limited genuine activity in state and local markets. The two posted records span different states (Illinois and Florida) and different issuing bodies (a state health department and a county government), but they do not establish a pattern of bevacizumab procurement. Readers should treat this code as presently inactive for bevacizumab sales and verify whether state formularies, Medicaid programs, or other state health-system buyers are actually using this code designation when acquiring biologic therapeutics, or whether they classify such pharmaceuticals differently in their procurement systems.